Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy Trotti

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Journal of Medical Imaging and Radiation Oncology|November 25, 2015
Outcomes of mucosal melanoma of the head and neckJessica M Frakes, Tobin J Strom, Arash O Naghavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology GroupDanny Rischin, Lester J Peters, Brian O'Sullivan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14K Kian Ang, Jonathan Harris, Adam S Garden, et al.
International Journal of Radiation Oncology, Biology, Physics|March 12, 2014
Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancerJonathan J Beitler, Qiang Zhang, Karen K Fu, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2008
Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)Adam S Garden, Jonathan Harris, Andy Trotti, et al.
The Lancet. Oncology|June 5, 2007
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology GroupAndy Trotti, Thomas F Pajak, Clement K Gwede, et al.
Oral Oncology|June 24, 2014
Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancerNikhil G Rao, Andy Trotti, Jongphil Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512)Andy Trotti, Qiang Zhang, Søren M Bentzen, et al.
Cancer Epidemiology|September 25, 2016
Treatment delays, race, and outcomes in head and neck cancerArash O Naghavi, Michelle I Echevarria, Tobin J Strom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003)Christine H Chung, James J Dignam, M Elizabeth Hammond, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Journal of Medical Imaging and Radiation Oncology|November 25, 2015
Outcomes of mucosal melanoma of the head and neckJessica M Frakes, Tobin J Strom, Arash O Naghavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology GroupDanny Rischin, Lester J Peters, Brian O'Sullivan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14K Kian Ang, Jonathan Harris, Adam S Garden, et al.
International Journal of Radiation Oncology, Biology, Physics|March 12, 2014
Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancerJonathan J Beitler, Qiang Zhang, Karen K Fu, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2008
Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)Adam S Garden, Jonathan Harris, Andy Trotti, et al.
The Lancet. Oncology|June 5, 2007
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology GroupAndy Trotti, Thomas F Pajak, Clement K Gwede, et al.
Oral Oncology|June 24, 2014
Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancerNikhil G Rao, Andy Trotti, Jongphil Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512)Andy Trotti, Qiang Zhang, Søren M Bentzen, et al.
Cancer Epidemiology|September 25, 2016
Treatment delays, race, and outcomes in head and neck cancerArash O Naghavi, Michelle I Echevarria, Tobin J Strom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003)Christine H Chung, James J Dignam, M Elizabeth Hammond, et al.
Pageof 7